TOPICAL FORMULATIONS OF DGAT1 INHIBITORS AND THEIR METHODS OF USE

Embodiments herein are directed to topical compositions comprising 2-(4-(4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl)cyclohexyl)acetic acid and a combination of one or more of the following components: benzyl alcohol, PEG 400, diisopropyl adipate, diethyl sebacate, dimethyl isosorbide, propylene glycol, 2-(2-ethoxyethoxy)ethanol, hexylene glycol, oleic acid, polysorbate 80, isopropyl myristate, glycerin, DMSO, water, butylated hydroxytoluene, phenoxyethanol, cellulose polymer, Carbomer Homopolymer Type B, and optionally one or more pharmaceutically acceptable topical excipients. The topical compositions may be used to treat a variety of skin conditions. 本文的实施例涉及局部用组合物，其包含2-(4-(4-(6-氨甲酰基-3,5-二甲基吡嗪-2-基)苯基)环己基)乙酸和一种或多种以下组分的组合：苯甲醇、PEG 400、己二酸二异丙酯、癸二酸二乙酯、二甲基异山梨醇、丙二醇、2-(2-乙氧基乙氧基)乙醇、己二醇、油酸、聚山梨醇酯80、肉豆蔻酸异丙酯、甘油、DMSO、水、丁基化羟基甲苯、苯氧乙醇、纤维素聚合物、B型卡波姆均聚物(Carbomer Homopolymer Type B)，以及任选地一种或多种药学上可接受的局部用赋形剂。所述局部用组合物可用于治疗多种皮肤病况。